These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 11996956)

  • 21. Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia.
    Ducobu J; VanHaelst L; Salomon H
    J Cardiovasc Pharmacol; 2003 Jan; 41(1):60-7. PubMed ID: 12500022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.
    Farnier M
    Expert Rev Cardiovasc Ther; 2012 May; 10(5):565-75. PubMed ID: 22651832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients.
    Sirtori CR; Montanari G; Gianfranceschi G; Sirtori M; Galli G; Bosisio E
    Eur J Clin Pharmacol; 1985; 28(6):619-24. PubMed ID: 3840743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
    Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.
    Farnier M; Marcereuil D; De Niet S; Ducobu J; Steinmetz A; Retterstøl K; Bryniarski L; Császár A; Vanderbist F
    Clin Drug Investig; 2012 Apr; 32(4):281-91. PubMed ID: 22350498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
    Schiel R; Bambauer R; Müller UA
    Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia.
    Contacos C; Barter PJ; Sullivan DR
    Arterioscler Thromb; 1993 Dec; 13(12):1755-62. PubMed ID: 8241095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
    Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of postprandial variation in triglyceridemia on low-density lipoprotein particle size.
    Blackburn P; Côté M; Lamarche B; Couillard C; Pascot A; Tremblay A; Bergeron J; Lemieux I; Després JP
    Metabolism; 2003 Nov; 52(11):1379-86. PubMed ID: 14624394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
    Farnier M; Perevozskaya I; Taggart WV; Kush D; Mitchel YB
    J Lipid Res; 2008 Dec; 49(12):2641-7. PubMed ID: 18669979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials.
    Ramjattan BR; Callaghan DJ; Theiss U
    Clin Ther; 2002 Jul; 24(7):1105-16. PubMed ID: 12182255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy studies].
    Pedro-Botet J; Flores-Le Roux JA
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():17-9. PubMed ID: 25043542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
    Farnier M; Retterstøl K; Steinmetz A; Császár A
    Diab Vasc Dis Res; 2012 Jul; 9(3):205-15. PubMed ID: 22228773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus.
    Niemeijer-Kanters SD; Dallinga-Thie GM; de Ruijter-Heijstek FC; Algra A; Erkelens DW; Banga JD; Jansen H
    Atherosclerosis; 2001 May; 156(1):209-16. PubMed ID: 11369016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients.
    Liang B; McMaster JC; Kroeger EA; Hatch GM; Mymin D; Dembinski T; Arthur G; Shen G; Man RY; Choy PC
    Mol Cell Biochem; 2000 Apr; 207(1-2):123-9. PubMed ID: 10888237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes.
    Kazama H; Usui S; Okazaki M; Hosoi T; Ito H; Orimo H
    Diabetes Res Clin Pract; 2003 Mar; 59(3):181-9. PubMed ID: 12590014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.